NEXUS Biosystems acquires Tecan’s REMP sample management business

NEXUS will acquire from Tecan all activities of the company’s REMP Sample Management business segment, and Tecan and NEXUS will collaborate on various additional product groups

Jeffrey Bouley
Register for free to listen to this article
Listen with Speechify
NEXUS Biosystems acquires Tecan's REMP sample management business

POWAY, Calif.—NEXUS Biosystems Inc., a global provider of automated sample management systems, ushered in a broader future for its products with the recent signing of an agreement to acquire Oberdiessbach, Switzerland-based  REMP AG, a wholly-owned subsidiary of the Tecan Group, along with some other related assets. The transaction should be closed within the next two months.

Under this agreement, NEXUS will acquire from Tecan all activities of the company's REMP Sample Management business segment, which is a worldwide provider of sample management systems and related sample management devices, instruments and consumables. In parallel with this transaction, Tecan and NEXUS plan to collaborate on various additional product groups.

The companies maintain that NEXUS and REMP truly complement one another, with NEXUS having strengths in high-speed, mid-size sample management systems and high-performance microtiter plates, while REMP provides leadership in small- and large-size automated sample management systems and high-quality sample containers and consumables. In addition, REMP has a strong customer base in Europe and Asia with a growing presence in the United States while NEXUS, coversely, enjoys a strong U.S. position and a growing presence in Europe and Asia.

"We are delighted with the opportunity to broaden our automated chemical and biological sample management offerings with the acquisition of Tecan's REMP Sample Management business. Together with our new colleagues from REMP, we look forward to continuing to provide innovative and reliable sample management solutions for our customers in the biopharmaceutical, biorepository, diagnostic, forensic, agrochemical and genomic research centers throughout the world," says John Lillig, CEO of NEXUS Biosystems. "The combined NEXUS-REMP resources will strengthen our capabilities and ensure continuity of first-class service and support for our customers as well as expand our product offerings for the growing global sample management community."

"We are certain that the sale of REMP to NEXUS Biosystems is the ideal solution. Our customers will benefit from the strong global market and service presence and the unparalleled innovation strength of the combined NEXUS-REMP entity in this industry segment," says Thomas Bachmann, CEO of Tecan. "At Tecan, we will increasingly focus resources on growth projects in our Life Sciences core markets and actively expand our end-customer business and our OEM activities."

Jeffrey Bouley

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue